Richard L. Borison

2.5k total citations
66 papers, 1.9k citations indexed

About

Richard L. Borison is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Richard L. Borison has authored 66 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 15 papers in Pharmacology and 15 papers in Cellular and Molecular Neuroscience. Recurrent topics in Richard L. Borison's work include Schizophrenia research and treatment (15 papers), Treatment of Major Depression (11 papers) and Electroconvulsive Therapy Studies (9 papers). Richard L. Borison is often cited by papers focused on Schizophrenia research and treatment (15 papers), Treatment of Major Depression (11 papers) and Electroconvulsive Therapy Studies (9 papers). Richard L. Borison collaborates with scholars based in United States, Japan and Canada. Richard L. Borison's co-authors include Bruce I. Diamond, B.I. Diamond, Lisa A. Arvanitis, Héctor Sabelli, Guy Chouinard, Aron D. Mosnaim, J.H. Gordon, John H. Gordon, Hans‐Jürgen Möller and Horst Müller and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Annals of Neurology.

In The Last Decade

Richard L. Borison

65 papers receiving 1.8k citations

Peers

Richard L. Borison

PMH

CMN

PHARM

Joseph F. Lipinski United States

J. Ananth Canada

Burt Angrist United States

Gohei Yagi Japan

Y.D. Lapierre Canada

Celeste A. Johns United States

Herbert Y. Meltzer United States

David L. Garver United States

H. Lôo France

Henrik Lublin Denmark

Joseph F. Lipinski United States

Richard L. Borison

874 ×0.8

PMH

337 ×0.6

CMN

235 ×0.6

PHARM

360 ×1.1

233 ×0.8

Citations per year, relative to Richard L. Borison Richard L. Borison (= 1×) peers Joseph F. Lipinski

Countries citing papers authored by Richard L. Borison

Since Specialization

Citations

This map shows the geographic impact of Richard L. Borison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard L. Borison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard L. Borison more than expected).

Fields of papers citing papers by Richard L. Borison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard L. Borison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard L. Borison. The network helps show where Richard L. Borison may publish in the future.

Co-authorship network of co-authors of Richard L. Borison

This figure shows the co-authorship network connecting the top 25 collaborators of Richard L. Borison. A scholar is included among the top collaborators of Richard L. Borison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard L. Borison. Richard L. Borison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borison, Richard L.. (1997). Recent Advances in the Pharmacotherapy of Schizophrenia. Harvard Review of Psychiatry. 4(5). 255–271. 30 indexed citations

Borison, Richard L.. (1996). The role of cognition in the risk‐benefit and safety analysis of antipsychotic medication. Acta Psychiatrica Scandinavica. 94(s389). 5–11. 25 indexed citations

Borison, Richard L., et al.. (1996). ICI 204,636, an Atypical Antipsychotic. Journal of Clinical Psychopharmacology. 16(2). 158–169. 238 indexed citations

Möller, Hans‐Jürgen, Horst Müller, Richard L. Borison, Nina R. Schooler, & Guy Chouinard. (1995). A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience. 245(1). 45–49. 100 indexed citations

Borison, Richard L., et al.. (1995). Paroxetine Treatment of Anger Associated with Depression. The Journal of Nervous and Mental Disease. 183(10). 666–666. 2 indexed citations

Borison, Richard L.. (1995). Clinical Efficacy of Serotonin-Dopamine Antagonists Relative to Classic Neuroleptics. Journal of Clinical Psychopharmacology. 15(1 Suppl 1). 24S–29S. 34 indexed citations

Marazziti, Donatella, et al.. (1995). Phenomenology and neurobiology of cocaine withdrawal: Are they related?. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 19(6). 1021–1034. 11 indexed citations

Gorman, Jack M., et al.. (1994). BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia. Neuropsychopharmacology. 10(1). 37–40. 49 indexed citations

Marazziti, Donatella, Alessandro Rotondo, Claudia Martini, et al.. (1994). Changes in Peripheral Benzodiazepine Receptors in Patients with Panic Disorder and Obsessive-Compulsive Disorder. Neuropsychobiology. 29(1). 8–11. 32 indexed citations

10.

Cunningham, Lynn, Richard L. Borison, John Scott Carman, et al.. (1994). A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression. Journal of Clinical Psychopharmacology. 14(2). 99???106–99???106. 130 indexed citations

11.

Borison, Richard L., et al.. (1992). Risperidone: clinical safety and efficacy in schizophrenia.. PubMed. 28(2). 213–8. 187 indexed citations

12.

Davidson, Lorinda, Manuel F. Casanova, David O. Taylor, et al.. (1992). Ventricle-to-Brain Ratio and Symptoms at the Onset of First-Break Schizophrenia. Schizophrenia Bulletin. 18(3). 427–435. 3 indexed citations

13.

Diamond, B.I., et al.. (1991). A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.. PubMed. 27(1). 67–71. 3 indexed citations

14.

Hitri, Ana, et al.. (1985). Neuroleptic blood levels and tardive dyskinesia.. PubMed. 40. 29–32. 1 indexed citations

15.

Borison, Richard L., et al.. (1982). New pharmacological approaches in the treatment of Tourette syndrome.. PubMed. 35. 377–82. 31 indexed citations

16.

Gordon, John H., Roger A. Gorski, Richard L. Borison, & Bruce I. Diamond. (1980). Postsynaptic efficacy of dopamine: Possible suppression by estrogen. Pharmacology Biochemistry and Behavior. 12(4). 515–518. 47 indexed citations

17.

Sabelli, Héctor, et al.. (1978). Phenylethylamine and brain function. Biochemical Pharmacology. 27(13). 1707–1711. 34 indexed citations

18.

Sabelli, Héctor & Richard L. Borison. (1976). 2-Phenylethylamine and other adrenergic modulators.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 15. 69–74. 2 indexed citations

19.

Zeller, E. A., et al.. (1976). Phenylethylamine: studies on the mechanism of its physiological action.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 15. 75–86. 7 indexed citations

20.

Sabelli, Héctor, et al.. (1976). Biochemical plasticity of synaptic transmission: a critical review of Dale's Principle.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 11(4). 481–524. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact